Over 50 missense mutations in the TARDBP gene have been identified [165-167], yet most drug screening models focus on just a subset of these mutations, which does not adequately capture the varied disease manifestations of TDP-43 proteinopathy. The gene discussed is TARDBP; the disease is proteostasis deficiencies.